QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=43F5B9F1017FB4BF269A0969F5600692;jsessionid=EE8A4BE610724FA91C72146637E4CFA4;jsessionid=1A61C3C3DE583697792260050939C19A;jsessionid=85997B838896CC8D8C64525E4885DCC7;jsessionid=784954E2CC2D694FD5B624B34B46E39E;jsessionid=4950FECD05F0B2A7097B8BFF82EBE527;jsessionid=CBDC88A38F5E639124F540A464C21426 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=43F5B9F1017FB4BF269A0969F5600692;jsessionid=EE8A4BE610724FA91C72146637E4CFA4;jsessionid=1A61C3C3DE583697792260050939C19A;jsessionid=85997B838896CC8D8C64525E4885DCC7;jsessionid=784954E2CC2D694FD5B624B34B46E39E;jsessionid=4950FECD05F0B2A7097B8BFF82EBE527;jsessionid=CBDC88A38F5E639124F540A464C21426